Inhaler

Aptar Awarded US FDA Contract to Study Opportunities for Low Global Warming Potential Propellants for Metered Dose Inhalers

Retrieved on: 
Monday, December 4, 2023
FDA, Health, Science, Pharmaceutical, Research, CQA, NYSE, Food, Inhaler, ATR, Multimedia, AptarGroup, Pharmaceutical industry, Pharma

AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges with developing low Global Warming Potential (low-GWP) propellant metered dose inhalers (MDIs).

Key Points: 
  • AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration (FDA) to study the challenges with developing low Global Warming Potential (low-GWP) propellant metered dose inhalers (MDIs).
  • View the full release here: https://www.businesswire.com/news/home/20231204794277/en/
    Moreover, Aptar’s study will help to define the potential target product profile of low-GWP propellant MDIs to achieve comparability in critical quality attributes (CQAs) to existing MDIs.
  • Additional capabilities Aptar can provide include pilot manufacturing / process, analytical methods offering alternative pathways to clinical trials, formulation development, metering valve technology and more.
  • Moreover, the study is expected to support the ongoing FDA efforts to provide guidance on the regulatory framework with respect to the evaluation and approval of low-GWP propellant MDIs.

Global Digital Dose Inhaler Market Primed for Remarkable Growth, Forecasted to Reach $53.32 Billion by 2030

Retrieved on: 
Friday, August 25, 2023
Inhaler, COPD, Asthma, MDI, Prevalence, DPI, Chronic lung disease, MEA, Economic development, U.S. FDA, Compound annual growth rate, Ageing, Chlorofluorocarbon, Digital health, FDC, Growth, Dry-powder inhaler, FDA, Pharmaceutical industry, Poultry farming

The global digital dose inhaler market is projected to experience substantial growth, with a projected market size of $53.32 billion by 2030, exhibiting an impressive Compound Annual Growth Rate (CAGR) of 19.4% from 2023 to 2030.

Key Points: 
  • The global digital dose inhaler market is projected to experience substantial growth, with a projected market size of $53.32 billion by 2030, exhibiting an impressive Compound Annual Growth Rate (CAGR) of 19.4% from 2023 to 2030.
  • This growth is driven by several key factors, including the increasing elderly population and the rising prevalence of chronic respiratory diseases.
  • These expansion strategies are expected to drive the adoption of digital dose inhalers and contribute to long-term growth and profitability.
  • This in turn has driven the demand for innovative respiratory devices, further stimulating growth in the digital dose inhaler market during the forecast period.

Global Bronchodilators Market Report 2023: Sector is Expected to Reach $28.75 Billion by 2030 at a CAGR of 3.29% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 14, 2023
Pharmaceutical, Health, Medical Devices, Real, COPD, Budesonide, Smoker, Asthma, Salbutamol, Global Initiative, Inhaler, American Lung Association, GOLD, SABA, AstraZeneca, Cipla, ICS, LMIC, Chronic obstructive pulmonary disease, Incidence, Patient, Risk, Growth, WHO, Global Initiative for Chronic Obstructive Lung Disease, FDA, Social media, Pharmaceutical industry, Teva

The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders.

Key Points: 
  • The demand for bronchodilators is growing significantly, owing to the increasing incidence of respiratory disorders.
  • The surging number of smokers is increasing the population with a heightened risk of lung conditions such as asthma and COPD.
  • For instance, as per WHO in 2021, there are over 1.3 billion smokers globally with 80% of them situated in LMIC's.
  • This creates a need for persistent use of bronchodilators in patients, thereby, accelerating the demand for bronchodilators.

Global Inhaled and Intranasal Products Contract Service Providers Market 2023: Sector to Reach $4.5 Billion by 2030 at a 8.5% CAGR - ResearchAndMarkets.com

Retrieved on: 
Monday, April 3, 2023
Health, Pharmaceutical, COPD, Social work, GSK plc, Asthma, Inhalation, Inhaler, United States National Library of Medicine, COVID-19, Chapter Three, Chronic obstructive pulmonary disease, National library, Department of Health and Social Care, Patient, Growth, NIH, Pharmaceutical industry

Furthermore, one of the most important breakthroughs at the start of the new millennium was the regulatory approval and commercialization of Advair/Seretide (GlaxoSmithKline).

Key Points: 
  • Furthermore, one of the most important breakthroughs at the start of the new millennium was the regulatory approval and commercialization of Advair/Seretide (GlaxoSmithKline).
  • Hence, contributing to the growth of the inhaled & intranasal products contract service providers market.
  • Metered- dose inhalers (MDIs) segment dominated the market with a revenue share of 50.6% in 2022.
  • Inhaled and Intranasal Products Contract Service Providers Market Variables, Trends & Scope

Global Digital Dose Inhalers Market Report to 2027: North America is Expected to Dominate the Market - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 21, 2023
Pharmaceutical, Health, Medical Devices, Inhaler, COPD, NORTH, Smoker, Asthma, MDI, Prevalence, DPI, Administration, Greenhouse gas, Dry-powder inhaler, Organization, Economy, Chlorofluorocarbon, Medicine, AMERICA, Chronic obstructive pulmonary disease, Death, Isocyanate, Digital technology, Azerbaijan and Organization for Economic Co-operation, Roflumilast, Metered-dose inhaler, Dust, Cystic fibrosis, Global Burden of Disease Study, Growth, WHO, Air pollution, CO2, DIGITAL, World Health Organization, Pharmaceutical industry, Geography

Therefore, the market for digital dose inhalers is estimated to grow at a substantial CAGR during the forecast period from 2022 to 2027.

Key Points: 
  • Therefore, the market for digital dose inhalers is estimated to grow at a substantial CAGR during the forecast period from 2022 to 2027.
  • One of the key aspect for driving the digital dose inhalers market is the rising prevalence of various respiratory disorders globally.
  • DIGITAL DOSE INHALERS MARKET SEGMENT ANALYSIS:
    Digital Dose Inhalers Market by Product Type (Dry Powder Inhalers and Metered Dose Inhalers), Application (Chronic Obstructive Pulmonary Disease, Asthma, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
  • NORTH AMERICA IS EXPECTED TO DOMINATE THE OVERALL DIGITAL DOSE INHALERS MARKET:
    Among all the regions, North America is expected to dominate the global digital dose inhalers market in the year 2021 and is expected to do the same during the forecast period from 2022-2027.

Global COPD Drug Delivery Devices Market Report 2022-2027: Rise in Focus on Smart or Digital Inhalers for Administration of COPD Drugs Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
General Health, Pharmaceutical, Health, Medical Devices, Online, Ansoff Matrix, Pharmacy Council of India, Market share, SWOT, USD, Porter's five forces analysis, Risk, Nebulizer, Growth, Inhaler, Pharmacy, Investment, Electron capture, COVID-19, Observation, Hospital, Market development, Geography, Retail, Risk management, Pharmaceutical industry

The Global COPD Drug Delivery Devices Market is segmented based on Product, Type, Distribution Channel, and Geography.

Key Points: 
  • The Global COPD Drug Delivery Devices Market is segmented based on Product, Type, Distribution Channel, and Geography.
  • The report presents a detailed Ansoff matrix analysis for the Global COPD Drug Delivery Devices Market.
  • The analyst analyses the Global COPD Drug Delivery Devices Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global COPD Drug Delivery Devices Market.

CIMSS Acquires RxCompli to Improve Patient Care and Quality of Life While Extending and Saving Patients Life

Retrieved on: 
Wednesday, December 14, 2022
Acquisition, Physician, Patient, Pillbox, Marketing, CIMSS, SMART, Inhaler, MD, RCM, CRM, EHR, Strategic planning, Pharmaceutical industry

Therefore, this acquisition will help prolong lives and lower costs for the patient.

Key Points: 
  • Therefore, this acquisition will help prolong lives and lower costs for the patient.
  • "We are very excited to see the impact our technology will have," says Sreenivasan Narayanan, CEO of RxCompli.
  • About RxCompli: RxCompli is a personalized caregiver that alerts patients to take their medications as prescribed.
  • Patients take the right medication and at the right time with the help of our sensors, SMART app, and reporting.

Smart Inhalers Market Size, Share & Trends Analysis Report By Type, By Indication, By Distribution Channel, By End-use, By Region And Segment Forecasts, 2022 - 2030

Retrieved on: 
Thursday, December 15, 2022
Asthma, Chronic Respiratory Disease, Medicine, Cavity ring-down spectroscopy, MDIS, Patient, Prevalence, Hospital, Degenerative disease, Inhaler, Chronic obstructive pulmonary disease, Dry-powder inhaler, Market share, Incidence, DPI, Pharmacy, Metered-dose inhaler, COVID-19, Health, Growth, COPD, USD, Cystic fibrosis, Pharmaceutical industry, Healthcare

View original content:https://www.prnewswire.com/news-releases/smart-inhalers-market-size-shar...

Key Points: 
  • Smart Inhalers Market Size, Share & Trends Analysis Report By Type (Dry Powdered Inhalers, Metered Dose Inhalers), By Indication (Asthma, COPD), By Distribution Channel, By End-use, By Region, And Segment Forecasts, 2022 - 2030
    The global smart inhalers market size is expected to reach USD 53.3 billion by 2030., expanding at a CAGR of 19.3% from 2022 to 2030.
  • According to the European Respiratory Society Congress, COPD is expected to affect over 480 million people in 2022 across the globe.
  • COVID-19 has increased the demand for smart inhalers due to the rising penetration of cutting-edge digital devices and solutions for respiratory and pulmonary care.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma

Retrieved on: 
Wednesday, November 9, 2022
Biotechnology, Pharmaceutical, General Health, Health, FDA, Health Technology, Clinical Trials, Other Health, Online, COPD, Safety, Research, Risk, Death, Link, Efficacy, Journal of Asthma and Allergy, Company, ADULT, Salbutamol, Conference, Papis Loveday, Inhaler, Risk factor, AstraZeneca, Dermatology, Spirometry, Internet, Jean-Jacques Bourdin, MDI, ICS, Science, Diagnosis, Global Initiative for Asthma, Patient, B93, Observational study, Ageing, ERS, BDA, SCS, Chronic lung disease, Week, Biopharmaceutical, Clare Lloyd, CDC, Veni, vidi, vici, Gastroenterology, Hospital, Atmosphere, Medicine, Clinical trial, Growth, NDA, Immunology, AES, ClinicalTrials.gov, Child, Rheumatology, Nature Research, Mortality, Protein Data Bank (file format), Budesonide, ID, Disease, Thomas Ford Chipp, Metabolism, Pharmaceutical industry, Silviculture, Asthma, FEV1, Oncology, Common

PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.

Key Points: 
  • PT027 is a potential first-in-class SABA/ICS rescue treatment for asthma in the US, to be taken as needed.
  • In March 2018, AstraZeneca and Avillion signed an agreement to advance PT027 through a global clinical development program for the treatment of asthma.
  • Following the successful approval of PT027, AstraZeneca has the option, upon certain financial payments, to commercialize the medicine in the US.
  • The Company aims to transform the treatment of asthma and COPD by focusing on earlier biology-led treatment, eliminating preventable asthma attacks, and removing COPD as a top-three leading cause of death.

Global Chronic Obstructive Pulmonary Disease Treatment Devices Report to 2027 - Market Insights, Competitive Landscape and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Health, Cardiology, Adult, Invacare, Competitive landscape, Patient, Particle size, Degenerative disease, Disease, Death, Microlife Corporation, COVID-19, Prevalence, Food, LAICA, Growth, Novartis, Inhaler, COVID, Genetics, Lupinus, PARI, Health care, Asthma, Mortality, LABA, CAGR, Hospital, Risk, Phlegm, FDA, Population, Air pollution, GlaxoSmithKline, Nebulizer, Disorder, AstraZeneca, Tobacco, MHRA, WHO, COPD, Medication, Cough, Incidence, Chronic obstructive pulmonary disease, World Health Organization, Dust, Medtronic, Metered-dose inhaler, Regulation of tobacco by the U.S. Food and Drug Administration, LAMA, Smoking, Awareness, Noble gas, Pharmaceutical industry, Dentistry, Geography

The "Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Obstructive Pulmonary Disease Treatment Devices - Market Insights, Competitive Landscape and Market Forecast-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global chronic obstructive pulmonary disease (COPD) treatment devices market is estimated to grow at a CAGR of 6.37% during the forecast period from 2022 to 2027.
  • Chronic Obstructive Pulmonary Disease Treatment Devices Market Dynamics:
    The chronic obstructive pulmonary disease treatment devices market is witnessing a growth in product demand owing to various reasons such as the growing prevalence of COPD due to long-term exposure to air pollution, secondhand smoke and dust, fumes and chemicals.
  • Furthermore, rise in consumption of tobacco among youth population is anticipated to bolster the market for chronic obstructive pulmonary disease treatment devices during the forecast period.